← Leaderboards
Ashish Ranjan
Oklahoma State University Stillwater
$5,626,451
Attributed
$7,272,593
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2014–25$2.5M$1.9M$1.3M$625K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,272,593 · 4
By mechanism
R01$3,870,084 · 2
R37$2,888,176 · 1
R15$514,333 · 1
Top collaborators
- Steven Fiering4 shared
- Nicole Franziska Steinmetz4 shared
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorMediatingTranslationsSuccessImmunosuppressionNeoplasm MetastasisMelanomaTumor AntigensCellsTumor ImmunityCanis FamiliarisImmunotherapyTumor MicroenvironmentInjectionsImmuneMalignant NeoplasmsInvestigationPreventNeoplastic CellTranslatingFocused Ultrasound TherapyInnovationResponseAdverse Effects
Grant awards (17)
Novel focused ultrasound enhanced calreticulin-nanoparticle for immune primed melanoma immunotherapy$1,239,509
R37 · FY2025 · CA · contact PI
Toward translation of a plant virus-based in situ vaccination nanotechnology$620,922
R01 · FY2025 · CA
Role of histotripsy synergized CD40 signaling in the re-engineering of cold tumors$504,109
R01 · FY2025 · CA · contact PI
Toward translation of a plant virus-based in situ vaccination nanotechnology$589,872
R01 · FY2024 · CA
Toward translation of a plant virus-based in situ vaccination nanotechnology$608,501
R01 · FY2023 · CA
Role of histotripsy synergized CD40 signaling in the re-engineering of cold tumors$442,535
R01 · FY2023 · CA · contact PI
Novel focused ultrasound enhanced calreticulin-nanoparticle for immune primed melanoma immunotherapy$286,470
R37 · FY2023 · CA · contact PI
Novel focused ultrasound enhanced calreticulin-nanoparticle for immune primed melanoma immunotherapy$72,048
R37 · FY2023 · CA · contact PI
Role of histotripsy synergized CD40 signaling in the re-engineering of cold tumors$21,054
R01 · FY2023 · CA · contact PI
Toward translation of a plant virus-based in situ vaccination nanotechnology$649,918
R01 · FY2022 · CA
Role of histotripsy synergized CD40 signaling in the re-engineering of cold tumors$433,173
R01 · FY2022 · CA · contact PI
Novel focused ultrasound enhanced calreticulin-nanoparticle for immune primed melanoma immunotherapy$345,260
R37 · FY2022 · CA · contact PI
Novel focused ultrasound enhanced calreticulin-nanoparticle for immune primed melanoma immunotherapy$329,555
R37 · FY2021 · CA · contact PI
Novel focused ultrasound enhanced calreticulin-nanoparticle for immune primed melanoma immunotherapy$315,862
R37 · FY2020 · CA · contact PI
Novel focused ultrasound enhanced calreticulin-nanoparticle for immune primed melanoma immunotherapy$299,472
R37 · FY2019 · CA · contact PI
Administrative supplement to promote institutional diversity$91,497
R15 · FY2015 · CA · contact PI
Image-guided tumor drug delivery by ultrasound-detected heat-released liposome$422,836
R15 · FY2014 · CA · contact PI